JW Therapeutics: Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

(marketscreener.com) SHANGHAI, May 30, 2024 /PRNewswire/ -- JW Therapeutics Co. Ltd , an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the preliminary clinical data on relmacabtagene autoleucel injection in adults with active systemic lupus erythematosus in...https://www.marketscreener.com/quote/stock/JW-CAYMAN-THERAPEUTICS-CO-119080133/news/Preliminary-Clinical-Data-on-Relma-Cel-Injection-in-Adults-with-Active-Systemic-Lupus-Erythematosus-46862833/?utm_medium=RSS&utm_content=20240530